BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal
SEC Notifies ImClone It May Bring Action Against Company
Auditor Raymond Weiss Finds “Incredible” Protocol Violations–26% Of Patients Were Ineligible For C225 Study
NCAB Grants Three MERIT Awards; Rimer To Leave NCI For Post At UNC
NRSAs Renamed For Kirschstein.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ









